AbbVie has agreed to pay Nxera $100 million upfront for worldwide rights to develop NXE0033744 in inflammatory bowel disease, with up to $1.37 billion in development and commercial milestones plus tiered royalties if the drug reaches market. The candidate is an oral EP4 receptor agonist that Nxera had previously pulled back from late last year during a pipeline and workforce restructuring.
The transaction extends a relationship that already included a 2020 inflammatory and autoimmune pact and a 2022 neuroscience deal. Strategically, it gives AbbVie another early-stage option in a disease area where it already has major commercial exposure through Humira, Skyrizi and Rinvoq, while allowing Nxera to monetize a program it had concluded was too costly and competitive to advance alone.
The Asset
Nxera has positioned NXE0033744 as a potential option for people with IBD who do not achieve satisfactory disease control. According to the company, the drug is designed to selectively activate EP4 receptors in the gastrointestinal tract in an effort to deliver anti-inflammatory effects and mucosal healing.
The biotech said it has already taken the candidate through a phase 1 trial. In its Nov. 4 release, Nxera said the study demonstrated a gut-restricted profile and target engagement through a reduction in indomethacin-induced intestinal permeability.
Why The Deal Matters
AbbVie is buying into a mechanism that sits outside its current leading IBD brands, which suggests the company is still looking for additional shots on goal despite its established position in the category. That matters because IBD remains both commercially attractive and developmentally difficult, making earlier-stage licensing a way to widen the pipeline without committing internal resources from day one.
For Nxera, the agreement is also a validation event for its NxWave drug discovery platform. CEO Christopher Cargill said AbbVie was the “ideal partner” to advance the program globally and test whether the biology can translate into measurable outcomes for people with IBD. He also tied the transaction to confidence in NxWave’s ability to consistently deliver.
Nxera’s decision to step back from NXE0033744 late last year did not reflect a lack of belief in the asset, based on Cargill’s earlier comments. At the time, he said the program had gone “extremely well” but described IBD as a “very, very complex and expensive area to be developing an asset.” AbbVie’s entry changes that equation by pairing the program with a company that already knows the market and can absorb the cost of global development.
